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Abstract.  Previous studies have reported that the cell- 
binding region of the neural cell adhesion molecule 
(N-CAM) resides in a  65,000-D  amino-terminal frag- 
ment designated Frl  (Cunningham, B. A.,  S. 
Hoffman, U.  Rutishauser, J.  J.  Hemperly, and G.  M. 
Edelman,  1983,  Proc.  Natl.  Acad.  Sci.  USA, 
80:3116-3120).  We have reported the presence of two 
functional domains in N-CAM,  each identified by a 
specific mAb, that are required for cell-cell or 
cell-substratum adhesion (Cole, G. J., and L.  Glaser, 
1986, J.  Cell Biol.,  102:403-412).  One of these do- 
mains is a  heparin (heparan sulfate)-binding domain. 
In the present study we have determined the topo- 
graphic localization of the heparin-binding fragment 
from N-CAM,  which has been identified by our labo- 
ratory. The BIA3 mAb recognizes a 25,000-D  heparin- 
binding fragment derived from chicken N-CAM, and also 
binds to a 65,000-D  fragment, presumably Frl, produced 
by digestion of N-CAM with Staphylococcus aureus V8 
protease. Amino-terminal sequence analysis of the iso- 
lated 25,000-D  heparin-binding domain of N-CAM 
yielded the sequence:  Leu-Gln-Val-Asp-Ile-Val-Pro-Ser- 
Gln-Gly. This sequence is identical to the previously 
reported amino-terminal sequence for murine and bovine 
N-CAM. Thus, the 25,000-D  polypeptide fragment is the 
amino-terminal region of the N-CAM molecule. We have 
also shown that the BIA3 mAb recognizes not only 
chicken N-CAM but also rat and mouse N-CAM, indicat- 
ing that the heparin-binding domain of N-CAM is evolu- 
tionarily conserved among different N-CAM forms. Addi- 
tional peptide-mapping studies indicate that the second 
cell-binding site of N-CAM is located in a polypeptide 
region at least 65,000  D from the amino-terminal region. 
We conclude that the adhesion domains on N-CAM 
identified by these antibodies are physically distinct, and 
that the previously identified cell-binding domain on Frl 
is the heparin-binding domain. 
T 
HE specific recognition between neuronal cell types is 
of critical  importance  during  neural  development. 
Cell-cell interactions have been the focus of many re- 
cent studies, and several distinct cell surface molecules have 
been implicated in neuronal cell-cell adhesion. These mole- 
cules include the neural cell adhesion molecule N-CAM (10, 
13,  17,  23,  29),  neuron-glial cell adhesion molecule (Ng- 
CAM) (11), L1 (21), and the nerve growth factor-inducible 
large external (NILE) glycoprotein (28).  N-CAM is the best 
characterized neural cell adhesion molecule to date, and has 
been  implicated  in  neuron-neuron  (24,  25,  29),  neu- 
ron-muscle (12), and neuron-glial (18, 27) adhesion. Previ- 
ous studies have examined the relationship between the chem- 
ical properties of N-CAM and its function, and have shown 
that a site required for homophilic binding of N-CAM (14) 
is localized to the amino-terminal region of the molecule (9). 
Studies in our laboratory have characterized a neural cell 
adhesion molecule that has now been identified as N-CAM 
(3-7). Using monoclonal antibodies, we have characterized 
the role of N-CAM in neuronal cell interactions. The BtA3 
mAb, which inhibits cell-cell adhesion, recognizes a 25,000- 
D polypeptide fragment from N-CAM that binds specifically 
to heparin or heparan sulfate (5). We have also demonstrated 
that heparin or heparan sulfate can inhibit N-CAM-mediated 
cell interactions (5, 6). A second mAb (C1H3)  also inhibits 
N-CAM-mediated cell-cell or cell-substratum adhesion but 
does not bind to the 25,000-D  fragment. In the present study 
we were interested in determining the topographical localiza- 
tion of the heparin-binding domain and how it may be related 
to the location of the cell-binding domain. Our data indicate 
that the heparin-binding domain is localized to the 25,000-D 
amino-terminal region of the N-CAM molecule. 
Materials and Methods 
Preparation of  mAb's 
The preparation and characterization of the B~A3 mAb (5), as well as other 
mAb's (3), has been described previously. The BtA3 mAb was produced by 
immunizing BALB/c mice with immunopurified N-CAM.  The B~A3 and 
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binding of each other to N-CAM. Neither antibody binds to carbohydrate, 
each reacts with protein isolated from cells labeled with [35S]methionine 
for 30 min, as described in reference 3, or with N-CAM synthesized by ret- 
ina cells in the presence of tunicamycin. 
Immunopurification of  N-CAM 
N-CAM was immunopurified from embryonic day  14 chicken brain tissue 
as previously described (7).  Briefly,  for each purification 100-200  brains 
were removed and homogenized in calcium-magnesium-free Hanks' solu- 
tion, and a membrane fraction was isolated. The membranes were then solu- 
bilized in PBS containing 1 mM EDTA and 0.5%  NP-40 (pH 8,3).  CIH3 
mAb,  which  reacts  with  N-CAM  (5),  was  coupled  to  cyanogen  bro- 
mide-activated Sepharose 4B  (•5-7  mg/ml).  The  solubilized extract of 
brain membranes was then incubated with the C~H3-Sepharose, and bound 
protein was eluted with PBS/1 mM EDTA/0.5 % NP-40 containing 0.05 M 
diethylamine (pH  11.5). 
Preparation of  Heparin-binding  Domain from N-CAM 
The heparin-binding domain was prepared from N-CAM by proteolytic 
digestion of immunopurified N-CAM  with  subtilisin protease  (5).  For 
amino-terminal sequencing of  the heparin-binding domain, 2 mg of  N-CAM 
was incubated with 40 Ixg of subtilisin protr,  ase (Sigma Chemical Co., St. 
Louis, MO) at 37°C for 1 h. Proteolysis was then stopped by the addition 
of phenylmethylsulfonyl fluoride (PMSF) and aprotinin (Sigma Chemical 
Co.). The digested N-CAM (in 0.Ix PBS) was then incubated with 1.5 rod 
of heparin-agarose (Sigma Chemical Co.) for 1.5 h at room temperature, 
and packed  into a  column.  After washing with 0.1×  PBS,  the heparin- 
binding fragment was eluted with 0.5  M  NaC1. 
Immunoblotting Analysis of  N-CAM 
To determine if the BjA3 mAb recognized a similar epitope in rat N-CAM, 
rat or chicken N-CAMs were digested with subtilisin protease (1:50  en- 
zyme/substrate ratio) and electrophoresed  on 10 % polyacrylamide gels. The 
proteolytic fragments were then transfenvA to nitrocellulose and reacted 
with BIA3 mAb as previously described (3,  5).  mAb binding was visual- 
ized using the avidin-biotin conjugate method (Vector  Laboratories, Inc., 
Burlingame, CA). 
Amino-terminal Sequencing of  Isolated 
Heparin-binding  Domain 
After isolation of the heparin-binding domain, the 25,000-D fragment was 
electrophoresed on  a  10%  polyacrylamide  mini-gel  and  stained  with 
Coomassie Blue for 10 min. The gel was then rapidly destained (15), and 
the bands corresponding to the 25,000-D  fragment were cut from the gel. 
The gel fragments were then processed for electroelution as described by 
Hunkapiller et al. (15). Alternatively, we transferred the 25,000-D fragment 
to polybrene-coated glass fiber filters (30). We initially attempted to obtain 
sequence analysis by electroblotting the 25,000-D fragment onto activated 
glass filter paper (1), but the fragment did not transfer out of the gel onto 
the glass filter paper. We thus initially used the electroelution method to ob- 
tain sequence information and then confirmed the amino-terminal sequence 
by transfer of the 25,000-D fragment to polybrene-coated glass fiber filters. 
After electroelution of the 25,000-D fragment or identification of the frag- 
ment on the glass fiber paper, amino-terminal sequence analysis was per- 
formed on a vapor phase sequencer (model 470A; Applied Biosystems, Inc., 
Foster City, CA) with identification of the phenylthiohydantoin amino acids 
on an on-line phenylthiohydantoin analyzer (model  120A; Applied Bio- 
systems, Inc.). 
Results 
Cunningham et al.  (9) demonstrated that a 65,000-D poly- 
peptide  fragment could be  derived  from N-CAM  by  au- 
todigestion of N-CAM,  and that this fragment (named Frl) 
could inhibit N-CAM-mediated cell binding. This fragment 
could also be isolated by digestion of N-CAM with Staphylo- 
coccus aureus V8 protease (14), and it was  shown that the 
amino-terminal amino acid sequence of Frl was identical to 
the intact protein (9). It was therefore concluded that the cell- 
binding domain of N-CAM was localized to the amino termi- 
nus of the molecule. 
In the present study we were interested in determining the 
topographical localization of the heparin-binding domain of 
N-CAM. Our laboratory has shown that heparin or the phys- 
iologically relevant ligand  heparan sulfate are involved in 
N-CAM-mediated cell-cell interactions (5,  6).  It has also 
been demonstrated that N-CAM undergoes a conformational 
change after the binding of heparan sulfate (7).  Therefore, 
it is of interest to examine how the alignment of the heparin- 
binding domain on the linear sequence of the N-CAM mole- 
cule is related to the cell-binding region. 
Our initial studies regarding the binding characteristics of 
the BIA3 mAb,  which recognizes the heparin-binding do- 
main of N-CAM,  showed that the BIA3 mAb reacts with a 
65,000-D  polypeptide  fragment  that  is  converted  to  the 
25,000-D fragment with more extensive protease treatment 
(5).  We  were  therefore  interested  in  determining  if  the 
65,000-D Frl fragment was identical to the fragment recog- 
nized by the B~A3 mAb. In preliminary experiments, we at- 
tempted  to  obtain  the  Frl  fragment  by  autodigestion  of 
N-CAM at 37°C,  as described by Edelman and co-workers 
(9). We only obtained limited amounts of the Frl fragment, 
which suggests that our N-CAM preparations do not contain 
significant quantities of protease activity; however, the Frl 
fragment  that  we  generated  reacted  with  the  B~A3 mAb 
(data not shown).  To obtain more direct evidence that the 
BIA3 mAb recognized the cell-binding domain of N-CAM, 
we treated N-CAM with S. aureus V8 protease and then per- 
formed an immunoblotting analysis  (Fig.  1).  As  shown in 
Fig.  1, lane a, when N-CAM is reacted with subtilisin pro- 
tease and then incubated with BIA3 mAb, both 65,000- and 
25,000-D polypeptide fragments are detected. After longer 
incubations with subtilisin protease, the 25,000-D fragment 
is the only fragment to which the BIA3 mAb can bind (5). 
Likewise, when N-CAM is digested with V8 protease, the 
BtA3  mAb  reacts  with  a  65,000-D  fragment,  which  is 
presumably the Frl fragment of N-CAM. These data there- 
fore indicate that the heparin-binding domain of N-CAM is 
probably localized to the 65,000-D amino-terminal region of 
the N-CAM protein, and raises the question of whether the 
cell-binding  domain  is  identical  to  the  heparin-binding 
domain. 
Figure 1.  The BIA3  mAb binds 
to the Frl fragment of N-CAM. 
10%tg  aliquots  of  N-CAM 
were  incubated  at  37°C  with 
100 ng of subtilisin (lane a) or 
S.  aureus V8 protease (lanes b 
and  c)  for  30  min.  Proteoly- 
sis was  then  inhibited by  the 
addition  of  PMSF,  and  the 
N-CAM fragments were elec- 
trophoresed  on  a  10%  gel, 
transferred  to  nitrocellulose, 
and  reacted  with  BtA3  or 
CtH3  mAb.  The  nitrocellu- 
lose was then incubated with biotinylated secondary antibody and 
Vectastain  ABC  reagent  (Vector  Laboratories,  Inc.).  Antibody 
binding was  visualized by  reaction with diaminobenzidine.  Note 
that the BIA3 mAb reacts with the 65,000-D  Frl  fragment. 
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Amino acid sequence  Reference 
25,000-D fragment  Leu-Gln-Val-Asp-Ile-Val-Pro-Ser-Gln-Gly 
Amino terminus, N-CAM  Leu-Gln-Val-Asp-Ile-Val-Pro-Ser-Gln-Gly-Glu-Ile-Ser-Val-Gly-Glu-Ser  22 
The amino acid sequence of the 25,000-D heparin-binding fragment  was determined as described under Materials and Methods. The sequence is shown through 
the first 10 residues, although cycles 11-15 yielded a low level  sequence  that also matched  the amino-terminal  sequence of N-CAM. Three independent analyses 
were performed. 
Our data in Fig.  1 also show that the C1H3 mAb, which 
inhibits cell-substratum and cell-cell adhesion (4-6), reacts 
with  a  polypeptide  fragment distinct  from Frl.  Since  the 
cin3 mAb does not bind to Frl, these data suggest that the 
C1H3 mAb binding site must be at least 65,000-D from the 
amino terminus of N-CAM.  These data also imply that at 
least two functional domains may exist on N-CAM and that 
the CIH3 mAb might bind to a region of the N-CAM mole- 
cule that participates in homophilic binding. 
To determine whether the heparin- and cell-binding do- 
mains are both localized to the amino-terminal region,  we 
performed amino-terminal amino acid sequence analysis of 
the isolated heparin-binding domain.  As shown in Table I, 
the amino acid sequence obtained for the 25,000-D fragment 
is Leu-Gln-Val-Asp-Ile-Val-Pro-Ser-Gln-Gly, which is iden- 
tical to the previously reported amino-terminal sequence for 
N-CAM  (22).  Thus,  these  data  indicate  that  the  heparin- 
binding domain of N-CAM is localized within the 25,000-D 
of the amino-terminal region of the molecule. 
Rougon and Marshak (22) produced antibodies that recog- 
nized a synthetic peptide sequence derived from the amino- 
terminal  sequence  of murine  and  bovine N-CAM.  These 
antibodies  cross-reacted  with  N-CAMs  from a  variety of 
species, which indicated that the amino-terminal domain iS 
highly  conserved.  Since  the  BjA3  mAb  recognizes  ~e 
heparin-binding domain from N-CAM and also blocks hepa- 
rin binding to N-CAM, as well as the adhesive functionof 
the molecule, and the heparin-binding domain is localized to 
the amino-terminal region of N-CAM, we asked whether this 
domain is also conserved among different N-CAM species. 
To test this possibility, rat N-CAM was digested with subtili- 
sin protease, transferred to nitrocellulose, and immunoblot- 
ted  with  BIA3  mAb.  As  shown  in  Fig.  2,  the  B1A3 mAb 
reacts with 25,000-D polypeptide fragments obtained from 
both chicken and rat N-CAM. However, reaction of the mAb 
with  rat  N-CAM  is  weaker  than  with  chicken  N-CAM, 
which suggests that the epitopes may not be identical in both 
Figure 2. The heparin-binding 
region  (BIA3 epitope)  of N- 
CAM is a conserved structural 
and functional domain.  10-lag 
aliquots  of  immunopurified 
chicken (lanes a and c) or rat 
N-CAM  (lane  b)  were  in- 
cubated with 200 ng of subtili- 
sin protease  for 1 h at 37°C. 
The  proteolytic  fragments 
were then analyzed by immu- 
noblotting  using  the  BIA3 
mAb  (lanes  a  and  b)  or  an 
anti-rat  N-CAM  antiserum 
(lane c) as described in Fig. 1. 
species.  In  Fig.  2  it  can  also  be  seen that  when  chicken 
N-CAM is digested with subtilisin protease and blotted with 
an anti-rat N-CAM antiserum, only the 25,000-D fragment 
is stained (Fig. 2, lane c). These data suggest that the most 
highly conserved region of chicken N-CAM, as detected by 
the  anti-rat  N-CAM  antiserum,  is  the  25,000-D  heparin- 
binding  fragment.  Alternatively,  this  fragment may be the 
most  protease-resistant  region  of the  N-CAM  molecules 
when treated with subtilisin protease. 
To confirm that the heparin-binding domain is a conserved 
structural  and  functional  domain  among various  N-CAM 
forms,  we  used the  B1A3 mAb to  immunopurify N-CAM 
from metabolically labeled  BC3H1  cells.  The  BC3H1  cell 
line is a mouse muscle-like cell line, and produces N-CAM 
(8). Fig. 3 shows the results of an experiment involving the 
metabolic  labeling  of cultures  of  BC3H1  cells  that  were 
grown in 20% FCS and thus were undifferentiated (20). Al- 
though  the  B1A3 mAb  did  not  immunopurify  significant 
quantities of labeled N-CAM from a BC3H1 cell extract, la- 
beled N-CAM was isolated from the conditioned medium 
of the  BC3H1  cells  (Fig.  3).  These data  indicate  that  the 
heparin-binding domain is conserved in mouse N-CAM, and 
also suggest that muscle cells (at least the BC3H1 cell line) 
may secrete larger amounts of N-CAM into the extracellular 
matrix than do neural cells. We have al~o analyzed N-CAM, 
immunopurified  from  adult  mouse  b~in  or  fiIC3H1 cells 
using  BIA3  mAb,  by  immunoblotting~ using  the  anti-rat 
N-CAM  antiserum.  These experiments! showed that  small 
amounts of N-CAM could be isolated from these cells using 
the BIA3 mAb (data not shown). The reason why only small 
amounts  of N-CAM  are  isolated  may  be  the  low  cross- 
reactivity between mouse N-CAM and the BIA3 mAb. 
Figure 3. I~entification of the 
B1A3  epitope  in  mouse  N- 
CAM.  Long-term  cultures  of 
BC3H1 cells  were  grown  in 
culture  as  described  under 
Materials and Methods. Cells 
were  then  labeled  overnight 
in  methionine-free  medium 
containing  1%  FCS  and  100 
I~Ci/ml  of  [35S]methionine. 
Conditioned medium from the 
cultures  was  mixed  with  an 
equal volume of PBS contain- 
ing  1% Triton X-100, and in- 
cubated overnight with either 
BIA3 or control ascites coupled to Sepharose 4B. The labeled pro- 
tein retained on the columns was then analyzed on an 8 % polyacryl- 
amide gel. Lane a, labeled protein isolated using BiA3-Sepharose; 
lane b, material eluted from the control ascites column.  The high 
molecular  weight  smear of labeled  protein  represents  immuno- 
purified N-CAM protein. 
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Figure 4.  Linear model depicting  the localization  of the heparin- 
and cell-binding domains of N-CAM. Tn a, the heparin-binding do- 
main is aligned at the amino terminus of the N-CAM molecule, and 
the cell-binding  domain is aligned in the carbohydrate-containing 
region of N-CAM. This is the putative C~I-I3 mAb-binding region. 
Thus, the cell- and heparin-binding domains are physically distinct 
regions of the  N-CAM molecule (see text for a more  detailed 
description). In b, the model is constructed based on data from this 
study and Cunningham et al.  (9). The only difference from the 
model in a is that the cell-binding domain is also aligned in the Frl 
fragment,  and  is  immediately  adjacent  to  the  amino-terminal 
heparin-binding domain. 
In  light  of these  data  demonstrating  that  the  heparin- 
binding  domain  of  N-CAM  is  localized  in  the  amino- 
terminal  region  of the  N-CAM  molecule,  we  have  con- 
structed a linear model of the N-CAM molecule (Fig. 4). 
Because our CIH3 mAb, which inhibits N-CAM-mediated 
cell-cell interactions, recognizes an epitope distinct from the 
B~A3 epitope (Fig.  1, lane c and reference 5),  we have as- 
signed the ~ell- or homophilic-binding domain to a more in- 
ternal region of the N-CAM molecule (Fig. 4 a). However, 
it is possible that the cell-binding domain described by Edel- 
man's laboratory (9) is also contained in the amino-terminal 
region of the N-CAM molecule (Fig.  4  b)  and additional 
studies should provide information regarding the precise lo- 
cation of this functional domain. 
Discussion 
Our aim in the present study was to examine the relationship 
between the structure and function of the heparin-binding 
domain  of  N-CAM.  Previous  studies  in  our  laboratory 
demonstrated that N-CAM contains a heparin-binding do- 
main (5), and this domain appears to be an integral compo- 
nent of the  N-CAM-mediated  cell  adhesion  mechanism. 
When  immunopurified  N-CAM  is  covalently  coupled  to 
glass  surfaces,  retinal  cell attachment is  inhibited by the 
cin3  mAb  and by heparin (5,  7).  Likewise,  the  isolated 
heparin-binding domain promotes cell attachment (5) and 
the B~Aa mAb inhibits  cell-cell adhesion (6).  These data 
therefore imply that the binding of  heparan sulfate to N-CAM 
is  required  for N-CAM-mediated  cell interactions.  Since 
previous studies had assigned a topographic location for the 
cell- or homophilic-binding domain (9), we were interested 
in  determining  the  topographic  location  of the  heparin- 
binding domain.  This was  of particular interest since the 
binding of heparan sulfate to N-CAM induces a conforma- 
tional change in the N-CAM protein (7). A similar confor- 
mational change has been described for fibronectin, and this 
leads to an increased affinity of  fibronectin for other extracel- 
lular matrix components and for the cell surface (16). 
Our initial experiments suggested that the heparin-binding 
domain of N-CAM was identical to Frl, which was previ- 
ously  reported  to  be  the  cell-binding  domain  (9).  After 
amino-terminal  amino  acid  sequencing  of  the  isolated 
heparin-binding  domain,  it  could  be  concluded  that  the 
heparin-binding domain was  also localized in the amino- 
terminal region of the N-CAM molecule. These results raise 
an  important  question:  is  the  previously  identified  cell- 
binding domain in fact the heparin-binding domain, or are 
both localized to the amino-terminal region of the protein? 
As shown in Fig. 4 a, we constructed a linear model for the 
structure of the N-CAM molecule that is based on the con- 
clusion that the cell-binding region described by Cunning- 
ham et al. (9) is the heparin-binding domain. In this model 
we aligned the heparin-binding domain in the amino-termi- 
nal region, and the cell-binding domain in a more internal 
position (>65,000-D from the amino terminus). The ration- 
ale for this model is that the C1H3 mAh inhibits N-CAM- 
mediated cell-cell adhesion (6) and binds to a polypeptide 
fragment that is distinct from Frl (Fig.  1, lane c and refer- 
ence 5).  These data would therefore suggest that the cell- 
binding  and heparin-binding  domains  are  located on dif- 
ferent polypeptide fragments.  However,  at  this  time,  the 
cell-binding region cannot be defined unequivocally because 
although the CIH3 mAb epitope is not a component of Frl, 
it is unclear what region of N-CAM will contain this epitope. 
However, it is clear that the C1H3 epitope must be at least 
40,000-D from the heparin-binding fragment. Thus, it is pos- 
sible that the C1H3 epitope is located at the cleavage site for 
Frl, if alternative cleavage of N-CAM occurs during proteol- 
ysis. In this case, any cleavage generating Frl would destroy 
the CtH3 epitope, and alternative cleavage sites would give 
rise to the fragments that the CIH3 mAb does recognize (5). 
Therefore, it is possible that the C1H3 mAb epitope is along 
the region of the N-CAM molecule extending from the cleav- 
age site of the Frl fragment to the carbohydrate-containing 
region, although this remains to be determined. 
It should be noted that the proposal that the cell-binding 
domain (which we are assuming is localized in a region that 
the CIH3 mAb binds)  is  located more internally than Frl 
depends  upon  several  assumptions.  The  first  is  that  the 
C1H3 mAb binds to a region of the N-CAM molecule that is 
involved in homophilic binding.  The second assumption is 
that the C1H3 mAb does not inhibit cell-cell adhesion by a 
nonspecific mechanism (i.e.,  steric hindrance).  The latter 
seems unlikely since the C1H3 epitope is separated from the 
B1A3 epitope by a minimum of 40,000 D on the linear map 
of N-CAM.  In addition, while B~A3 blocks the binding of 
heparin sulfate to N-CAM,  C~H3 does not show this effect 
(7),  hence steric blockage of the heparin binding  site by 
CtH3 seems  unlikely.  However, until  further experiments 
are conducted, we have constructed two linear models to de- 
scribe the relationship between N-CAM structure and func- 
tion (Fig. 4 a and b). The second model, depicted in Fig. 4 
b, is based on the hypothesis that both the cell- and heparin- 
binding  domains  are  components  of Frl.  Since  the  cell- 
binding domain was  identified as  a  65,000-D  polypeptide 
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fragment, it is possible that the cell-binding domain is local- 
ized at least 25,000 D  from the amino terminus (Fig. 4 b). 
If this is the case, then it could be proposed that after heparan 
sulfate (contained on a heparan sulfate proteoglycan) binding 
to  N-CAM,  the conformational change in  N-CAM  could 
modulate the binding of cells to the cell-binding domain, 
which is in close proximity to the heparin-binding domain. 
This  model  could therefore account for the  experimental 
results of Cunningham et al. (9) and of this study.  However, 
because the C1H3 mAb is not a component of Frl, in this 
model  the  CIH3  mAb  would  be  expected to  inhibit  cell 
adhesion nonspecifically, since the cell-binding domain is 
not associated with the CIH3 epitope. At this time we favor 
the proposal (Fig. 4 a) that the cell- and heparin-binding do- 
mains reside on distinct polypeptide fragments and that the 
previously described  cell-binding  domain  is  the  heparin- 
binding domain. Additional support for this hypothesis could 
be obtained by the isolation of a polypeptide fragment, dis- 
tinct from the heparin-binding domain, that can promote (or 
inhibit, depending on the assay) neural cell attachment. It is 
also noteworthy that other mAb's that recognize N-CAM and 
inhibit cell-cell adhesion have now been shown to react with 
the 25,000-D heparin-binding domain (Frelinger, L., and U. 
Rutishauser, personal communication). This discussion as- 
sumes that only two sites on N-CAM are responsible for its 
adhesion function. Clearly other sites, possibly overlapping, 
could be required for this function and are not identified by 
these antibodies. 
Because the studies of Cunningham et al. (9) demonstrated 
that  the  cell-binding  domain  is  localized  to  the  amino- 
terminal region of N-CAM, we have also considered a third 
possibility to  reconcile the  results  of their  study and the 
present  work.  It  is  interesting  to  speculate  that  the  cell- 
(homophilic)  and  heparin-binding  domains  are  identical, 
and  that  the  heparin-binding  domain  is  responsible  for 
homophilic binding. In this mechanism, the heparin-binding 
domain would be binding to a region of N-CAM that is simi- 
lar in structure to the carbohydrate moiety of heparan sulfate 
proteoglycan. For example, previous studies have described 
the presence of HNK-1/L2 carbohydrate epitope on N-CAM, 
and this carbohydrate epitope is proposed to be involved in 
neuronal cell interactions (19). The precise structure of the 
HNK-1/L2 epitope on N-CAM is unknown, and it is unclear 
whether this carbohydrate epitope is an O- or N-linked moi- 
ety.  However, this carbohydrate structure appears  to be a 
3-sulfated  glucuronyl  carbohydrate  chain  (also  found  in 
glycolipids in the nervous system; reference 2), and it is in- 
teresting to speculate that it may be able to interact with the 
heparin-binding domain of N-CAM. 
We have also demonstrated in this study that the heparin- 
binding domain is conserved among N-CAMs from a variety 
of other species. The 25,000-D fragment could be derived 
from rat N-CAM, and the B~A3 mAb could immunopurify 
small amounts of N-CAM from a mouse muscle cell line. An 
interesting result of the muscle experiment is  that greater 
amounts of N-CAM appear to be secreted from BC3HI cells 
into the conditioned medium when compared with neural 
cells.  Since  these  cells  produce  adherons  that  promote 
cell-substratum attachment (26), it is possible that N-CAM 
is involved in cell attachment to these adherons; however, 
adherons from these cells also contain fibronectin and other 
known matrix molecules (26).  The demonstration that the 
BIA3 mAb reacts with N-CAM from other species therefore 
supports  the  data  of Rougon  and  Marshak  (22),  which 
showed that the amino-terminal domain of N-CAM is a con- 
served structure. The fact that the heparin-binding domain 
is also exposed on the cell surface, which is a prerequisite 
for interaction with neighboring cells, is consistent with their 
results. 
In conclusion, in these studies we have described the topo- 
graphic  location  of  the  heparin-binding  domain  and  a 
cellular-binding domain from N-CAM, and have shown that 
the heparin-binding domain is a conserved structure local- 
ized in the amino-terminal region of the N-CAM molecule. 
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